Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia News

News
Real-World Clinical Outcomes Among Patients With CLL, With and Without Deletion 17p, Treated With First-Line Ibrutinib
05/26/2022
Findings from a recent study identified an unmet need for more effective first-line therapeutic options for patients with chronic lymphocytic leukemia/small lymphocytic leukemia and deletion 17p, despite the advent of ibrutinib.
Findings from a recent study identified an unmet need for more effective first-line therapeutic options for patients with chronic lymphocytic leukemia/small lymphocytic leukemia and deletion 17p, despite the advent of ibrutinib.
Findings from a recent study...
05/26/2022
Journal of Clinical Pathways
News
Comparing the Cost-Effectiveness of First-Line Treatments of Chronic Lymphocytic Leukemia
05/11/2022
When compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies may be associated with less health benefits at higher cost, and that the targeted therapies achieve greater benefits at higher cost.
When compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies may be associated with less health benefits at higher cost, and that the targeted therapies achieve greater benefits at higher cost.
When compared with...
05/11/2022
Journal of Clinical Pathways
News
Time to Discontinuation of First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL
04/08/2022
Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...
Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...
Patients with CLL or SLL who...
04/08/2022
Journal of Clinical Pathways
News
The Impact of Atrial Fibrillation on Morbidity and Mortality Among Patients With CLL
03/08/2022
Findings from a recent study suggest that patients with CLL with atrial fibrillation may be at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke.
Findings from a recent study suggest that patients with CLL with atrial fibrillation may be at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke.
Findings from a recent study...
03/08/2022
Journal of Clinical Pathways
News
Real-World Risk of Infusion Reactions and Efficacy of Frontline Obinutuzumab-Chlorambucil for CLL
02/10/2022
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of...
02/10/2022
Journal of Clinical Pathways
News
Ibrutinib Safe, Effective for the Treatment of Relapsed/Refractory CLL
12/07/2021
Findings from a real-world study suggest that using single-agent ibrutinib for relapsed/refractory CLL is safe and effective in routine clinical practice.
Findings from a real-world study suggest that using single-agent ibrutinib for relapsed/refractory CLL is safe and effective in routine clinical practice.
Findings from a real-world study...
12/07/2021
Journal of Clinical Pathways
News
First-Line Venetoclax Plus Obinutuzumab is Cost-Effective for Unfit Patients With CLL
11/19/2021
Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment regimen for unfit patients with CLL.
Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment regimen for unfit patients with CLL.
Fixed duration venetoclax plus...
11/19/2021
Journal of Clinical Pathways
News
Real-World Cardiovascular Risks for Patients With CLL Receiving Ibrutinib
09/22/2021
Study findings suggest patients with CLL taking ibrutinib are at increased risk for atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke.
Study findings suggest patients with CLL taking ibrutinib are at increased risk for atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke.
Study findings suggest patients...
09/22/2021
Journal of Clinical Pathways
News
Infusion Facility Budget Impact of Different Bendamustine Formulations for CLL and NHL
08/04/2021
Small-volume, short-duration infusions of bendamustine may result in lower acquisition costs and lower administration labor costs compared to large-volume, long-duration infusions, in patients with CLL and indolent NHL.
Small-volume, short-duration infusions of bendamustine may result in lower acquisition costs and lower administration labor costs compared to large-volume, long-duration infusions, in patients with CLL and indolent NHL.
Small-volume, short-duration...
08/04/2021
Journal of Clinical Pathways
News
Economic Burden of Systemic Therapy Among Medicare Patients With CLL
06/07/2021
Study findings highlight substantial economic burden incurred by Medicare among patients with CLL who initiated systemic therapy in routine practice, citing adverse events as a large contributor to the high overall cost of CLL management.
Study findings highlight substantial economic burden incurred by Medicare among patients with CLL who initiated systemic therapy in routine practice, citing adverse events as a large contributor to the high overall cost of CLL management.
Study findings highlight...
06/07/2021
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use